Related Experiment Video

Updated: Jun 19, 2026

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.9K

Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized

Neal D Shore1, Thomas B Powles2, Jens Bedke3

  • 1START Carolinas/Carolina Urologic Research Center, Myrtle Beach, SC, USA. nshore@auclinics.com.

Nature Medicine
|July 21, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.6K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.4K

Related Experiment Videos

Last Updated: Jun 19, 2026

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.9K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.6K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.4K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

Trial design drives outcomes: harmonising efficacy across BCG-unresponsive bladder carcinoma in situ trials.

BJU international·2026

Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

METTL5-mediated rRNA modification controls prostate cancer progression through the IRF7/DNA2 axis and mitophagy regulation.

Oncogene·2026

Enzalutamide in biochemically recurrent prostate cancer: clinical implications from EMBARK for real-world practice.

Future oncology (London, England)·2026

Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer.

International journal of clinical oncology·2026

Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial.

Prostate cancer and prostatic diseases·2026

Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

Nature medicine·2026

Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial.

Nature medicine·2026

Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial.

Nature medicine·2026

Reproducibility in biomedical research.

Nature medicine·2026

Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial.

Nature medicine·2026

Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

Nature medicine·2026

Bone Anabolic Treatment in Patients With Chronic Kidney Disease: A Systematic Review.

Basic & clinical pharmacology & toxicology·2026

Xiaoaiping Injection Combined with Chemotherapy Versus Chemotherapy Alone for Breast Cancer: A Systematic Review and Meta-Analysis.

Journal of visualized experiments : JoVE·2026

Add-on Moxibustion and Detoxification Enema Alleviates Symptoms and Improves Renal Function in Chronic Kidney Disease: A Retrospective Cohort Study.

Journal of visualized experiments : JoVE·2026

Mitochondrial mechanisms underlying spatial immune phenotypes in non‑small cell lung cancer: Implications for ICI response and cold‑to‑hot tumor conversion (Review).

Oncology reports·2026

Loperamide enhances the radiosensitivity of cervical cancer cells via ferroptosis induction.

Oncology reports·2026

Clinical Outcomes of Endoscopic Submucosal Dissection and Transoral Videolaryngoscopic Surgery for Superficial Hypopharyngeal Cancers.

Journal of gastroenterology and hepatology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us